Title:BRD4 Protein as a Target for Lung Cancer and Hematological Cancer
Therapy: A Review
Volume: 24
Issue: 14
Author(s): Mengmeng Zhang, Yingbo Li, Zilong Zhang, Xin Zhang, Wei Wang, Xiaomei Song and Dongdong Zhang*
Affiliation:
- School of Pharmacy, Shaanxi University of Chinese Medicine, Xianyang, Shaanxi, 712046, P.R. China
Keywords:
BRD4 protein, hematological cancer, lung cancer, mechanism, targeted therapy, neoplastic diseases.
Abstract: The BET protein family plays a crucial role in regulating the epigenetic landscape of
the genome. Their role in regulating tumor-related gene expression and its impact on the survival
of tumor cells is widely acknowledged. Among the BET family constituents, BRD4 is a significant
protein. It is a bromodomain-containing protein located at the outer terminal that recognizes
histones that have undergone acetylation. It is present in the promoter or enhancer region of the target
gene and is responsible for initiating and sustaining the expression of genes associated with tumorigenesis.
BRD4 expression is significantly elevated in various tumor types. Research has indicated
that BRD4 plays a significant role in regulating various transcription factors and chromatin
modification, as well as in repairing DNA damage and preserving telomere function, ultimately
contributing to the survival of cancerous cells. The protein BRD4 has a significant impact on antitumor
therapy, particularly in the management of lung cancer and hematological malignancies,
and the promising potential of BRD4 inhibitors in the realm of cancer prevention and treatment is
a topic of great interest. Therefore, BRD4 is considered a promising candidate for prophylaxis and
therapy of neoplastic diseases. However, further research is required to fully comprehend the significance
and indispensability of BRD4 in cancer and its potential as a therapeutic target.
